| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net loss | ||||||
-69,442 | -31,585 | -50,183 | -37,002 | - | - | - |
Net loss | ||||||
- | - | - | - | -21,860 | -24,027 | -8,729 |
Non-cash items: | ||||||
Change in fair value of derivative liability (Note 9) | ||||||
- | - | - | 81 | -52 | 949 | 962 |
Stock-based compensation (Note 5(d)) | ||||||
7,683 | 4,698 | 3,839 | 1,966 | 1,506 | 854 | 349 |
Acquired in-process research & development (Note 3) | ||||||
47,716 | - | - | - | - | - | - |
Stock-based purchase of patent rights | ||||||
- | - | - | - | - | 186 | - |
Unrealized foreign exchange loss and others | ||||||
- | - | - | - | -580 | -549 | -41 |
Depreciation and amortization | ||||||
340 | 289 | 360 | - | - | - | - |
Unrealized foreign exchange (gain) loss | ||||||
-263 | -452 | -349 | -185 | - | - | - |
Financing costs | ||||||
- | - | - | - | - | 320 | 14 |
Fees and penalty on bank loan repayment | ||||||
- | - | - | - | - | 100 | - |
Amortization and extinguishment of remaining discount on preferred stock upon conversion of preferred stock | ||||||
- | - | - | - | - | 1,884 | 386 |
Changes in operating assets and liabilities: | ||||||
Receivable, prepayments and deposits | ||||||
-290 | -1,041 | 905 | 109 | 96 | 17 | - |
Prepayments and deposits | ||||||
- | - | - | - | - | - | 102 |
Accounts payable and other liabilities | ||||||
-2,244 | -6,472 | 1,822 | 4,815 | -450 | 3,614 | 1,180 |
Net cash used in operating activities | ||||||
-15,394 | -31,577 | -44,718 | -30,226 | - | - | - |
Cash used in operating activities | ||||||
- | - | - | - | -20,268 | -17,486 | -7,823 |
Investing activities | ||||||
Acquisition of Neoleukin Therapeutics, Inc., net of cash acquired | ||||||
191 | - | - | - | - | - | - |
Purchase of investments | ||||||
- | - | 5,995 | 106,442 | 60,703 | 36,475 | 2,821 |
Proceeds from maturity of investments | ||||||
- | 56,000 | 70,500 | 59,097 | 13,196 | 12,990 | - |
Purchase of property and equipment | ||||||
879 | 49 | 494 | 713 | 26 | 114 | 11 |
Net cash used in investing activities | ||||||
-688 | 55,951 | 64,011 | -48,058 | - | - | - |
Sale of property and equipment | ||||||
- | - | - | - | - | 26 | 192 |
Cash provided by (used in) investing activities | ||||||
- | - | - | - | -47,533 | -23,573 | -2,640 |
Financing activities | ||||||
Public offering of common stock (Note 8(e)) | ||||||
86,216 | - | - | 75,368 | 98,038 | 53,130 | - |
Preferred stock issued | ||||||
- | - | - | - | - | - | 18,003 |
Public offering costs (Note 8(e)) | ||||||
5,525 | - | - | 4,692 | 6,210 | 5,251 | 224 |
Proceeds from exercise of stock options | ||||||
1,555 | 602 | 438 | 440 | 1,120 | - | - |
Bank loan repayment, fees and penalty | ||||||
- | - | - | - | - | -2,600 | 2,392 |
Payment on finance lease obligations | ||||||
9 | 32 | 15 | 4 | - | - | - |
Net cash provided by (used in) financing activities | ||||||
82,237 | 570 | 423 | 71,112 | - | - | - |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | ||||||
10 | -48 | 15 | -53 | - | - | - |
Net change in cash, cash equivalents and restricted cash during the period | ||||||
66,165 | 24,896 | 19,731 | -7,225 | - | - | - |
Public offering costs | ||||||
- | - | - | - | - | - | 587 |
Cash provided by financing activities | ||||||
- | - | - | - | 92,948 | 45,279 | 19,584 |
Effect of exchange rate changes on cash and cash equivalents | ||||||
- | - | - | - | -527 | -320 | -116 |
Net change in cash and cash equivalents during the period | ||||||
- | - | - | - | 24,620 | 3,900 | 9,005 |
Supplemental disclosure of cash flow information: | ||||||
Interest paid | ||||||
1 | 4 | 4 | 1 | - | - | - |
Interest paid | ||||||
- | - | - | - | - | 32 | 23 |
Interest received | ||||||
1,544 | 1,684 | 1,342 | 695 | 325 | 91 | 26 |
Non-cash investing and financing activities: | ||||||
Receivables, prepayments and deposits acquired through the issuance of common stock | ||||||
560 | - | - | - | - | - | - |
Property, equipment and intangibles acquired through the issuance of common stock | ||||||
1,693 | - | - | - | - | - | - |
Accounts payable, finance lease and other liabilities assumed through the issuance of common stock | ||||||
1,673 | - | - | - | - | - | - |
Accrued purchase of property & equipment | ||||||
- | - | -77 | 77 | - | - | - |
Accrued offering costs | ||||||
- | - | -30 | - | 35 | - | 790 |
Assets acquired through capital leases | ||||||
- | - | - | 65 | 11 | - | - |
Exercise of warrants on a net settlement basis | ||||||
- | - | - | 43 | - | - | - |